亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

山東濟南市偉都化工有限公司  

原料藥,醫藥中間體司產品包括抗腫瘤類原料藥,消炎鎮痛類原料藥,減肥類原料藥,吡啶類中間體,吡啶硼酸類中間體,苯硼酸類中間體,嘧啶類中間體,碘吡啶類中間體,咪唑類中間體,吲哚類中間體及其他類中間體等,可定制生產。

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:洪劍
  • 電話:0531-55503856
  • 傳真:0531-88873470
  • QQ:2497947303
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 佐匹克隆 43200-80-2
佐匹克隆 43200-80-2
單價 155.00 / 千克對比
銷量 暫無
發貨 山東濟南市付款后3天內
庫存 1000千克起訂1千克
品牌 佐匹克隆 43200-80-2
型號 43200-80-2
規格 佐匹克隆 43200-80-2
過期 長期有效
更新 2011-09-23 17:07
 
詳細信息


佐匹克隆 43200-80-2

英文名  Zopiclone
別名  4-Methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; Imovane
產品名稱  佐匹克隆; (5RS)-6-(5-氯吡啶-2-基)-7-[(4-甲基哌嗪-1-基)羰氧基]-5,6-二氫吡咯并[3,4-b]吡嗪-5-酮

分子式  C17H17ClN6O3
分子量  388.81
CAS 登錄號  43200-80-2
EINECS 登錄號  256-138-9

©2025 山東濟南市偉都化工有限公司 版權所有   技術支持:化工網   訪問量:6032  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |